Dynamics of the Immune Response to COVID-19 / Infection by SARS-CoV-2

Browse trials for

• Infections 6,687
• Communicable Diseases 4,452
• COVID-19 7,640
• Virus Diseases 914

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 173 is below the median of 240 across 2,136 observational studies indexed under Infections.

Lead sponsor

Universität des Saarlandes is the lead sponsor of 64 studies on the registry; 16 are open to participants now.

Study population

Groups and cohorts

• COVID-19 patients
• Healthy controls
• Non-COVID-19 patients with respiratory tract infection

Primary outcomes

1. Differential expression of biomarkers between COVID-19 and controls

   Differential expression of TRAIL, IP-10, CRP, and their computational integration in subjects with COVID-19, as compared to control subjects.

   Time frame: up to 90 days

2. Differential expression of biomarkers between severe and non-severe COVID-19

   Differential expression of TRAIL, IP-10, CRP, and their computational integration in subjects with COVID-19, who require more extensive medical intervention (i.e., exhibit severe symptoms), i.e. severe infection vs. non-severe infection

   Time frame: up to 90 days

3. Correlation of biomarkers with disease severity

   Correlation between host-immune biomarkers including TRAIL, IP-10, CRP, and their computational integration for predicting disease severity in patients with COVID-19, where measures of severity include ICU admission, respiratory failure, mechanical ventilation, septic shock, non-respiratory organ failure, and mortality.

   Time frame: up to 90 days

Secondary outcomes

1. Biomarkers depending on therapy

   Differential expression of TRAIL, IP-10, CRP, and their computational integration in subjects with COVID-19 with or without specific therapy.

   Time frame: up to 90 days

2. Biomarkers depending on bacterial co-infection

   Differential expression of TRAIL, IP-10, CRP, and their computational integration in subjects with COVID-19 with or without bacterial co-infection.

   Time frame: up to 90 days

3. Correlation of biomarkers with viral load

   Correlation between host-immune biomarkers including TRAIL, IP-10, CRP, and their computational integration with infectiousness, i.e. e.g. viral load.

   Time frame: up to 90 days

Publications

• Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshtein L, Kriger O, Bamberger E, Fonar Y, Yacobov R, Wolchinsky R, Denkberg G, Dotan Y, Hochberg A, Reiter Y, Grupper M, Srugo I, Feigin P, Gorfine M, Chistyakov I, Dagan R, Klein A, Potasman I, Eden E. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. PLoS One. 2015 Mar 18;10(3):e0120012. doi: 10.1371/journal.pone.0120012. eCollection 2015. PubMed 25785720 ↗
• van Houten CB, de Groot JAH, Klein A, Srugo I, Chistyakov I, de Waal W, Meijssen CB, Avis W, Wolfs TFW, Shachor-Meyouhas Y, Stein M, Sanders EAM, Bont LJ. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study. Lancet Infect Dis. 2017 Apr;17(4):431-440. doi: 10.1016/S1473-3099(16)30519-9. Epub 2016 Dec 22. PubMed 28012942 ↗
• Tegethoff SA, Danziger G, Kuhn D, Kimmer C, Adams T, Heintz L, Metz C, Reifenrath K, Angresius R, Mang S, Rixecker T, Becker A, Geisel J, Jentgen C, Seiler F, Reichert MC, Frohlich F, Meyer S, Rissland J, Ewen S, Wagenpfeil G, Last K, Smola S, Bals R, Lammert F, Becker SL, Krawczyk M, Lepper PM, Papan C. TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study. Int J Infect Dis. 2022 Sep;122:178-187. doi: 10.1016/j.ijid.2022.05.051. Epub 2022 May 25. PubMed 35643306 ↗